7 results about "Malignant Neoplastic Disease" patented technology

The device consists of three parts, one part is a base adhered to the surface of a human body, and the three parts are respectively adhered to the periphery of a to-be-punctured part on the surface of the human body during use; one end of each second part connecting rod is connected with a round hole in the base, and the other end of each second part connecting rod is connected with an annular fixing ring penetrating through the microwave ablation needle; the third part is a connecting ring sleeved on the microwave ablation needle, and a small circular ring is arranged on the third part in a turnover trisection mode and used for being connected with the fixing rod. When microwave ablation treatment is carried out on a malignant tumor patient, according to a treatment plan, three bases are attached to the periphery of a to-be-ablated part, a microwave ablation needle is sleeved with the connecting rings, the bases and the connecting rings are connected through the connecting rods, and the needle inserting direction of microwave ablation is adjusted by changing the positions of the connecting rods and the connecting rings. Therefore, the puncture needle cannot deviate from the correct direction due to the gravity effect and the respiratory movement of a patient in the puncture process and the CT scanning process.

The application belongs to the technical field of biological probes, and relates to a PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe and a preparation method thereof. The PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe comprises a core, a covalent organic framework and a PD-L1 antibody, the core comprises a superparamagnetic nanoparticle, the covalent organic framework is coated on the surface of the core, and the PD-L1 antibody is combined on the surface of the covalent organic framework. The PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe prepared by the application can be transported into the body across the membrane, smoothly enter a PD-L1 positive malignant tumor lesion, and perform Raman imaging to microscopically distinguish the tumor boundary.

The present disclosure relates to compounds of the formulae herein (e.g, Formula (II)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, which are inhibitors of a GTPase (e.g., cell division control protein 42 homolog (Cdc42)). The present disclosure also provides pharmaceutical compositions comprising the compounds, pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating diseases (e.g., malignant neoplastic diseases, diseases associated with aging) by administering to a subject in need thereof the compounds, pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof.

The present disclosure relates to a novel benzotriazine dioxide and a pharmaceutical composition thereof. The benzotriazine dioxide has a structure of formula (I). The benzotriazine dioxide can be used alone or in combination with other drugs to treat or alleviate benign and malignant tumor disorders in the liver, bile duct, pancreas, stomach, esophagus, kidney, colon, lung, brain (glioma), malignant glioma, breast, ovary, cervical, head and neck, skin, melanoma, prostate, fibrosarcoma, sarcoma, thyroid gland, etc.

Described are devices, systems, and methods for controlled delivery of therapeutic and / or diagnostic agent(s) in a tissue in a subject. In particular, provided are carrier devices in which the agent(s) may be enclosed. One or more carrier devices may be injected or implanted at target loci in a tissue, such as in a malignant neoplasm. The agent(s) may diffuse from the carrier devices in a predetermined and controlled manner. Further provided are methods for developing optimized parameters for intraparenchymal placement of carrier devices and diffusion of the agent(s), to achieve an optimized therapeutic exposure in the target tissue. Further provided are devices and systems for intraparenchymally placing carrier devices at desired loci in a tissue.

The invention provides a rehabilitation management method and system for nausea and vomiting of a tumor chemotherapy patient, and relates to the technical field of medical treatment. The main control chip can input the attribute characteristics of the patient, the medication characteristics of the chemotherapeutic drugs for the malignant tumors and the physiological characteristics of the first patient into a pre-trained first vomiting degree prediction model to predict the first vomiting degree of the patient; inputting the attribute characteristics of the patient and the first vomiting degree of the patient into a vomiting rehabilitation management strategy model, and determining each massage manipulation for the Neiguan point of the wrist of the patient, the massage sequence of each massage manipulation, and the massage duration, massage force and massage frequency of each massage manipulation; according to the determined massage sequence of each massage manipulation and the massage duration, massage force and massage frequency of each massage manipulation, the simulation massage hand is controlled to massage the Neiguan point of the wrist of the patient, and the nausea and vomiting symptoms caused after the malignant tumor patient takes chemotherapy drugs can be accurately prevented and improved.

To provide a pharmaceutical composition for treatment of malignant neoplastic disease.SOLUTION: A pharmaceutical composition comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such an IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.SELECTED DRAWING: None